Cost-effectiveness of HIV screening in high-income countries: A systematic review by Bert, Fabrizio et al.
Title: Cost-effectiveness of HIV screening in high-income countries: A systematic review 
 
Authors: Fabrizio Berta, Maria Rosaria Gualanoa,∗, Paolo Bianconeb, Valerio Bresciab, 
Elisa Camussia, Maria Martoranaa, Silvana Secinarob, Roberta Siliquinia 
 
Affiliations: 
a Department of Public Health Sciences, University of Turin, Italy 
b Department of Management, University of Turin, Italy 
 
Corresponding Author: 
* Prof. Maria Rosaria Gualano 
Department of Public Health Sciences, University of Turin 
Via Santena 5 bis, 10126 Turin, Italy. 
E-mail address: mariarosaria.gualano@unito.it 
 
Keywords: 
HIV screening; Cost-effectiveness; High-income countries; Adult population 
  
Abstract 
Introduction 
Over 2 million people in high-income countries live with HIV. Early diagnosis and treatment present 
benefits for infected subjects and reduce secondary transmissions. Cost-effectiveness analyses are 
important to effectively inform policy makers and consequently implement the most cost-effective 
programmes. Therefore, we conducted a systematic review regarding the cost-effectiveness of HIV 
screening in high-income countries. 
Methods 
We followed PRISMA statements and included all papers evaluating the cost-effectiveness of HIV 
screening in the general population or in specific subgroups. 
Results 
Thirteen studies considered routine HIV testing in the general population. The most cost-effective 
option appeared to be associating one-time testing of the general population with annual screening of 
high-risk groups, such as injecting-drug users. Thirteen studies assessed the cost-effectiveness of HIV 
screening in specific settings, outlining the attractiveness of similar programmes in emergency 
departments, primary care, sexually transmitted disease clinics and substance abuse treatment 
programmes. 
Discussion 
Evidence regarding the health benefits and cost-effectiveness of HIV screening is growing, even in 
low-prevalence countries. One-time screenings offered to the adult population appear to be a valuable 
choice, associated with repeated testing in high-risk populations. The evidence regarding the benefits 
of using a rapid test, even in terms of cost-effectiveness, is growing. Finally, HIV screening seems 
useful in specific settings, such as emergency departments and STD clinics. 
  
1. Introduction 
In 2012, over 35 million people lived with human immunodeficiency virus (HIV) infection 
worldwide, and of these, approximately2.2 million lived in high-income countries [1]. Moreover, a 
large percentage of the infected population are unaware of their status; for example, in the US, 21% 
of people living with HIV ignore this condition [2]. Knowledge of the HIV-serostatus and early 
treatment can improve both the survival and the quality of life of infected subjects[3]. In addition to 
the individual benefits, the early identification of HIV may have a role in reducing the transmission 
from index patients to uninfected persons [4–6]. Indeed, people’s knowledge of their condition 
substantially reduces their at-risk behaviours [4–6]. In addition, antiretroviral therapy (ART) 
effectively reduces the viral load [4–6]. Given the high burden of HIV infection worldwide [1] and 
the high number of people unaware of their serostatus [2], HIV disease represents a significant public 
health problem. Since highly sensitive and specific diagnostic tests are available and early treatment 
significantly alters the disease course, universal HIV screening may represent a valuable tool of 
secondary prevention [7]. Moreover, the progressive introduction of innovative rapid tests, promising 
to provide results in less than 30 min with extremely good sensitivity (from 95% to 98%) and 
specificity (99% with whole-blood specimens), represents a further resource for HIV-prevention [8]. 
Indeed, rapid tests may decrease losses to follow-up, a major issue of standard testing, which requires 
a second visit to communicate the results [9]. In this context, the “Centers of Disease Control and 
Prevention” (CDC) has recommended that all untested adults be screened, while high-risk populations 
should receive at least one test annually [10]. In particular, screening should be performed routinely 
for all patients aged 13–64 years, unless the prevalence of undiagnosed HIV infection is lower than 
0.1% [10]. The main recognized risk groups are injecting-drug users (IDUs), sex workers, men who 
have sex with men (MSM), sex partners of HIV-infected persons and partners of at-risk subjects [11]. 
However, an interesting work of 2007 highlighted how the majority of the US states present HIV 
testing requirements inconsistent with the previously cited CDC recommendations [12]. 
In the literature, limited experience with universal HIV screening can be retrieved, particularly 
regarding emergency departments (EDs) [13,14].To effectively inform policy-makers and since 
accurate data regarding HIV prevalence are often lacking, screening programmes should monitor 
costs and effectiveness to avoid screening implementation causing increased health expenditures. In 
addition, these recommendations cannot be effectively implemented if patients with HIV diagnoses 
do not remain engaged in care [11,12]. The European Centre for Disease Prevention and Control 
(ECDC)has recommended repeated HIV testing for high-risk people. How-ever, economic modelling 
has not found annual testing to be cost-effective, even in populations with a high prevalence [15]. 
Conversely, the French Public Health Guidelines recommend HIV screening of the entire adult 
population [16]. In addition, the UK National Guidelines underline that universal HIV screening 
should be offered whenever the prevalence exceeds 2 in 1000 in the population [17]. An analysis 
regarding the cost-effectiveness of different HIV screening strategies is extremely important to 
effectively inform policy makers and consequently implement the most cost-effective programmes. 
Indeed, similar analyses effectively support decisions in the healthcare field [18]. These economic 
evaluations compare different programmes from the perspectives of both the cost and the 
consequences [19].  
Recently, many studies have investigated the cost-effectiveness of HIV screening, considering 
different settings, target populations and screening frequencies [9,20–24]. Nevertheless, data 
regarding this topic are often heterogeneous, considering both the screening strategy and the study 
methodology [20,22,24–28]. In public health, the cost-effectiveness analysis expresses costs in euros 
or dollars and health benefits in units of health, such as a life saved or a quality-adjusted life-year 
(QALY) gained [29].A cost-effectiveness ratio is calculated between money expended and health 
obtained [29]. The incremental cost-effectiveness ratio(ICER) is often used to compare the costs and 
effectiveness of health interventions and to provide an evident guide, for example, when policy-
makers have established an explicit standard or threshold for what should be considered cost-effective 
[29]. Particularly, the thresholds based on per capita national incomes are one of the possible 
approaches to decide if a health programme represents a good investment for the national health-care 
system [30]. However, the exact cost-effectiveness threshold is still debated. Regarding this issue, 
the World Health Organization (WHO) guidelines identify as cost-effective an incremental cost-
effectiveness ratio (ICER) lower than three times the per-capita gross domestic product (GDP) [30]. 
Therefore, in our analysis, we decided to adopt this threshold to assess cost-effectiveness; indeed, this 
threshold could be applied to countries with different incomes [30]. The cost-effectiveness of 
universal HIV screening is widely assessed in high-prevalence areas such as Sub-Saharan African 
countries [31,32]. However, increasing evidence has also out-lined the economic convenience of 
similar programmes among low-prevalence populations [21,22]. Indeed, the clinical benefits, 
deriving from the early diagnosis and the availability of highly active antiretroviral therapies, could 
make the screening not only acceptable and efficient but also economically suitable in such 
epidemiological settings [21,22]. 
To our knowledge, no previous review has investigated the cost-effectiveness of HIV-screening in 
developed countries. Therefore, we conducted a systematic review regarding the cost-effectiveness 
of HIV-screening, focusing on countries defined as high-income by the World Bank [33]. We decided 
to consider these countries in as much more comparable both in economic and epidemiologic terms. 
Aside from cost-effectiveness, we aimed to individuate the optimal testing frequency and the 
population to whom to actively offer HIV tests. Moreover, our review intended to investigate thecost-
effectiveness of rapid tests compared to standard antibody tests. 
 
2. Methods 
For our systematic review, we employed Preferred Reporting Items for Systematic Review and Meta-
analysis (PRISMA) statements [34]. We considered all papers reporting data about the cost-
effectiveness of HIV screening, investigating the following three databases: Cost-Effectiveness 
Analysis Registry (CEA), PubMed and Scopus. From May to June 2016, two researchers (EC and 
MM) independently conducted a systematic search of the scientific literature employing the following 
strings: “HIV screening” AND cost effectiveness; “HIV test” AND cost effectiveness. 
To select the eligible studies, we used the inclusion criteria reported below: 
• Cost-effectiveness studies regarding HIV screening 
• Papers written in English, French, Italian or Spanish 
• Publication date from 2000 
• Studies regarding high-income countries (considering the World Bank classification) [24]. 
We chose the time limit previously cited (from 2000 onwards) because it coincides with the wide 
introduction of effective ART regimens [35]. We considered both simulation models and clinical 
trials.  
Furthermore, we stated the following exclusion criteria: 
• Articles focusing exclusively on therapy cost-effectiveness 
• Articles considering only cost analyses 
• Articles assessing vertical transmission screening 
• Articles considering blood donor screening or screening of healthcare professionals. 
We decided to exclude the works regarding blood donors because the screening strategies for this 
group are already well-established [36,37]. Moreover, we decided to exclude the works regarding 
healthcare workers in order to focus on the general population and on the main at-risk groups, widely 
recognized in the literature as MSM and IDUs [11]. 
First, the investigators independently sorted the retrieved sources by title and abstract. This first 
procedure excluded irrelevant and duplicated results. Then, we collected the eligible studies available 
for a full-text review, completing our search through the reference list assessment. Finally, the 
researchers independently evaluated the retrieved articles using the above-reported inclusion and 
exclusion criteria. 
2.1. Data extraction 
The researchers summarized the retrieved results independently, extracting the information of interest 
and solving any disagreement by consensus. For each article, we collected data about the country in 
the study, the intervention, the target population, the HIV prevalence or incidence, the setting, the 
outcome, the perspective, the time horizon, the costs and the results. Then, we analysed the retrieved 
studies in two groups: “HIV screening in the general population and high-risk groups” and “HIV 
screening in specific settings”. We compared the studies in each group considering the 
methodological characteristics, HIV epidemiology in the considered setting/country, and the findings. 
We also found the potential source of heterogeneity. 
2.2. Quality assessment 
To limit the risk of introducing biases into our systematic review, the quality of these studies was 
assessed using the Drummond 10-item scale [38]. The scale is composed of 10 main questions, each 
further organized in sub-items. For example, the first item investigates the organization of the 
analysis, identifying the objective of the study. Most of the remaining questions consider the 
evaluation of the costs and consequences of the interventions in the study [38]. Two researchers (EC 
and MM) independently assessed the quality of the studies included in the review, using the afore 
mentioned Drummond scale. Then, the final score was obtained from the mean of the two partial 
scores. Each question of the scale was worth 1 point, with a potential score ranging from 0 to 10 
points. We decided to exclude all the works with a score below 7. However, in the conclusions and 
discussion of our work, we assigned a major weight to the deductions deriving from the studies with 
a higher quality assessment. 
 
Figure 1 - Flow chart of the included and excluded studies. Information flow chart of the 
different steps of the systematic review. 
 
 
3. Results 
Our search obtained 581 results. After excluding duplicates and irrelevant sources, we collected 54 
articles. Then, relying on full-text reading, we came to the conclusive number of 26 articles (see Fig. 
1) [4,9,20–28,39–53]. The papers were excluded after a full-text reading because they did not meet 
the eligibility criteria previously mentioned, they referred to unrelated topics or they presented a 
quality assessment score below 7. Overall, the quality of the retrieved studies, as assessed through 
the Drummond 10-item scale, was good (see Tables 1 and 3). Indeed, all the selected works scored at 
least 8 points on the considered scale, and over 73% of the studies presented a score greater than or 
equal to nine. Fourteen studies considered routine HIV testing in the adult population, considering 
the general population and high-risk groups (see Tables 1 and 2) [4,9,20–22,24,28,39,41–44,53]. The 
majority of the studies in the analysis adopted a societal perspective[4,22,24,28,39–41,43,44,53]. 
Two studies chose an intermediate perspective, called modified societal, not accounting for all 
indirect costs [20,21]. Nearly all the studies considered the long-term effects of HIV screening 
(lifetime or 20 years) [4,20–22,24,28,41–44,53], except for those of Farnham et al. (who considered 
in their mathematical model a 1-year perspective) [39] and Stevinson et al.(1-month perspective) [9]. 
In the latter case, the short-term analysis is justified by the study’s aim of comparing two types of 
HIV testing (rapid or traditional testing) [9]. For the economic analysis, the reference year ranged 
from 2001 [44] to 2012 [20,22], with a discounting rate of 3% [4,21,22,24,28,39,41–44,53]. Four 
studies focused on European countries, specifically the UK [22], Portugal[20], France [21] and Russia 
[42]. Ten studies considered the screening implementation in the US [4,9,24,28,39–41,43,44,53]. 
Nearly all the studies compared universal screening of the adult population with current testing, 
considering different screening frequencies[4,20–22,39,41–43]. Moreover, the papers, with few 
exceptions[4,9,39,42,53], took into account targeted strategies towards high-risk groups. The authors 
agreed in identifying as high-risk groups MSM, IDUs and people from endemic countries [20–
22,24,40,41]. Regarding the general population, the authors focused on adults(15–64 or 18–69 years) 
[4,20–22,24,40,41,43], except for Tole et al., who offered screening to a younger cohort (15–49 years) 
[42], and Sanders et al., who focused on older adults [53]. All the studies, except that of Stevinson et 
al. [9], employed a dynamic model simulating HIV progression, assessing the long-term 
consequences of HIV disease [4,20–22,28,39–44,53]. To assess HIV progression, these papers 
considered HIV viral loads, CD4 counts, ART therapy, opportunistic infections, morbidity and 
natural history data [4,20–22,28,39–43,44,53]. 
3.1. One-time routine HIV screening in the general population 
France, the UK and the USA presented a comparable, low HIV prevalence [4,9,21,22,24,28,39–
41,43,44,53], while Russia and Portugal presented a higher HIV burden [20,42]. Considering the 
undiagnosed HIV prevalence, which ranged in these countries from 0.03% [22] to 0.16% [20], a 
universal one-time screening was the best option in the UK, France and Portugal [20–22]. In the 
British study, the most cost-effective option was associating one-time testing of the general 
population with annual screening of high-risk groups [22]. The universal one-time screening yielded 
D 28,000/QALY (not considering secondary transmissions) and 7400D /QALY (accounting for 
secondary transmissions) in Portugal and D 57,400/QALY in France [20,21]. In the UK, a programme 
providing annual HIV testing to MSM, IDUs, and people from HIV-endemic countries coupled with 
one-time screening of all other adults reported an ICER of £17,500/QALY gained [22]. In Russia, the 
one-time universal screening resulted in $13,396/QALY, and accounting for the screening impact on 
secondary transmissions, the cost-effectiveness further improved [42]. 
 
 
 
 
 
The US studies assessed the cost-effectiveness of one-time screening of the general population, 
considering the US prevalence [4,39,41,43]. In particular, in cases of lower HIV prevalence (0.1%), 
the one-time screening would cost $60,700/QALY [43]. Sanders et al. found a lower ICER of one-
time HIV screening ($15,078/QALY), considering the additional sexual partner benefits, and 
41,736$/QALY excluding HIV transmission. [4]. Incorporating costs and benefits, the authors 
estimated that one-time screening would cost $194 more than the current practice per patient [4]. A 
further analysis investigated the cost-effectiveness of expanded screening, expanded ART or the 
combination of these two interventions. The screening consisted of one-time testing for adults in 
addition to annual testing for high-risk individuals. The expanded ART programme increased the 
number of patients receiving appropriate therapy ($20,300/QALY), preventing 7,3% of new 
infections [41]. The screening intervention prevented 6.7% of expected infections (81,991 infections), 
at a cost of $22,382/QALY compared to the status quo [41]. Routine screening every three years 
among all risk groups had an ICER of $112,094/QALY gained compared to the status quo, while 
annual HIV screening of all adults was less cost-effective, at $143,930/QALY gained [41]. The 
combination strategy prevented 17.3% of expected infections, more than expected, summing up the 
two strategies benefits, with a cost-effectiveness rate of $21,580/QALY [41]. Another interesting 
study employed a mathematical model to assess how much policymakers should spend for HIV 
screening. Despite the main data derived from sexually transmitted disease (STD) clinics, the authors 
widely varied these parameters, adapting them to the general population. In the base case, the 
screening programme resulted in cost savings that remained until a prevalence of 0.09% and remained 
cost-effective until 0.03% [39]. In the base case, the cost per new HIV diagnosis was $2528, and the 
cost per infection averted was $40,516 [39]. Only one study determined a higher cost for general 
population screening with an ICER of$113,000/QALY [44]. This difference could be partially 
explained by the background characteristics considered (undiagnosed prevalence 0.1%, annual 
incidence 0.01%) and by other parameters such as background testing, adherence to ART, and rates 
of linkage to care. However, one-time screening significantly improved the average survival among 
HIV-infected patients [44]. Moreover, screening in the US population could avert up to 10 secondary 
transmissions per 100,000 [44]. All previous studies considered HIV screening for adults up to 65 
years old, and only one study estimated the implementation of similar programmes targeted to older 
subjects. In this context, the screening cost-effectiveness depended mainly on age and HIV 
prevalence. In individuals with partners at risk and an HIV prevalence of 0.5%, the screening 
presented an ICER below $60,000/QALY in the entire age cohort (55–75 years). Instead, decreasing 
the HIV-prevalence to 0.1%, the screening would cost more, with an ICER of $91,410/QALY for 65-
year-old patients, and exceeded this value in older people [53]. Considering the health benefits, the 
authors estimated the increase in survival deriving from the early identification of HIV. These benefits 
mainly depended on age and decreased for older patients. For a 65-year-old patient, screening 
increased the life expectancy by 0.58 years. These benefits reduced to 0.30 years for a 75-year-old 
HIV-infected patient. Considering current US population data, one-time screening could save over 
120,000 life years [53]. In addition, the authors considered the potential role of abbreviated 
counselling. Including this counselling in the model was associated with better cost-effectiveness 
ratios. In a sensitivity analysis considering people up to 75 years old with no partner at risk, using a 
screen with abbreviated counselling would cost less than $100,000/QALY if the HIV prevalence  is 
0.1% and less than $50,000/QALY at a prevalence of 0.5% [53]. Moreover, the considered studies 
outlined the individual health benefits of HIV screening in terms of the CD4 count at diagnosis 
[20,21] and life expectancy [4,42,44]. In particular, screening identification and treatment resulted in 
an increase in life expectancy of 1.52 years [4]. In addition, the authors assessed the public health 
role considering secondary transmissions [20,21,42,44] and the favourable impact on risk behaviours 
[22,42]. For example, one-time screening effectively reduced the lifetime numbers of transmissions 
to 0.95, 0.35, and 0.12 partners among men who have sex with men, heterosexual men, and 
heterosexual women, from 1.12, 0.42, and 0.14, respectively [4]. The main findings were robust 
across the sensitivity analysis [4,9,20–22,24,28,39,41–44,53]. However, the most influencing 
parameters were the impact on behavioural changes [22,42], HIV prevalence [20–22], and linkage to 
care [20,21,42]. Despite the influencing role of HIV prevalence, the one-time universal screening was 
considered cost-effective until a prevalence of 0.02% [42] or 0.05% in the USA [4]. Finally, the 
screening cost-effectiveness was equally assessed using standard ELISA antibodies [21,22,41] or 
HIV rapid testing [20,28,39,44]. Specifically, a study focused on this topic to individuate the optimal 
testing algorithm, comparing the standard algorithm (rapid test + confirmatory WB), requiring a 
second visit to communicate test results, to a rapid algorithm (rapid test + confirmatory rapid test), 
consenting to give same-day results. The first strategy presented a loss to follow-up exceeding 25%. 
The study outlined the benefits of a rapid algorithm, saving over $146 per positive person identified. 
Moreover, a confirmatory rapid test, aside from reducing loss to follow-up, correctly identified 
positive results as well as a standard Western blot [9]. There was a mean interval of 11.4 days until 
the test and notification of infection with the standard testing algorithm; by contrast, patients testing 
positive with the rapid test received the notification on the same day [9]. This study used a short-term 
perspective (one-month); how-ever, it gives interesting insights regarding the use of rapid tests in 
HIV screening [9]. Moreover, since several new infections are related to acute HIV infections, the 
detection of these individuals is important. A 2011 study analysed the cost-effectiveness of different 
screening strategies identifying acute infections. Indeed, the newer fourth-generation tests could 
significantly reduce the window period (average, 17 days) compared to the third-generation ELISA 
tests. Moreover, pooled nucleic acid amplification testing (NAAT) can detect HIV-RNA 11 days after 
infection. Then, the paper compared HIV screening using fourth-generation immunoassays to a 
screen for acute infection through pooled NAAT. Universal HIV screening with a fourth-generation 
immunoassay presented a cost variable from $100,000 to $580,000 per QALY, adding 2.3–2.7 
million QALYs over 20 years [40]. 
3.2. Repeated HIV screening in general population 
Several studies considered the opportunity of repeated screening in the general population 
[4,20,22,28,40,42]. For example, in the UK, although one-time screening was the more attractive 
strategy, annual testing of all adults would cost £67,400/QALY gained under the optimistic 
assumption, and £106,000/QALY in case of no partnership reduction [22]. In contrast, considering 
the French incidence and prevalence data, increasing the universal screening frequency exceeded any 
considered cost-effectiveness threshold [20]. Conversely, in Russia, with a prevalence of 1.2% and 
an incidence of 0.075%, 5-year universal testing would cost $27,696/QALY, and accounting for 
secondary transmissions, the cost-effectiveness further improved [42]. Furthermore, in the US, 
repeated screening could be a feasible choice for policy-makers [4]. Indeed, screening every five 
years, compared with a one-time screening programme, would cost 57,138 $/QALY, but the authors 
found an ICER below 50,000 $/QALY in settings with a higher incidence of infection [4]. Moreover, 
HIV screening significantly reduced HIV secondary transmission in all the considered groups (MSM, 
and heterosexual men and women) [4]. However, at the base-case incidence, screening every five 
years, slightly affects the lifetime numbers of transmissions [4]. Another study clearly highlighted 
how repeated screening in the general population translated to increased costs and scarce incremental 
benefits [44]. Considering alternative types of tests, such as NAAT, the annual repetition of such an 
analysis in the general population would far exceed any proposed threshold (from $3.2 million to $4.7 
million per QALY gained) [40]. Specifically, an additional study investigated the optimal screening 
frequency in HIV testing, assuming a test-and-treat scenario, in which each HIV-positive individual 
received ART immediately. In this scenario, the cost-effectiveness of HIV-screening was 
$36,342/quality-adjusted life-years (QALYs). Indeed, for low incidence (0.01%), the optimal testing 
uptake was approximately 2 years, considering 100,000$/QALY as the threshold, with an additional 
cost of $213.68 per person. Comparing these results with CDC recommendations, the higher 
frequency of screening for one million low-risk individuals would bring an additional health gain of 
5880 QALYs at a cost of $213.7 million and $36,342 $/QALY. Decreasing the cost-effectiveness 
threshold to 50,000$/QALY, the optimal testing interval for a low-risk population increased to 5 
years. Considering the traditional ART initiation, the optimal time interval almost doubled [28]. 
3.3. High-risk groups  
Considering high-risk groups, the repeated screening became increasingly more interesting [20–
22,24,28,43,44]. Despite the wide range of cost-effectiveness thresholds considered, the cost-
effectiveness of repeated screening among IDUs and MSM was widely assessed [20–22,24,28,43,44]. 
As previously mentioned, the more cost-effective choice was providing annual HIV testing to MSM, 
IDUs, and people from HIV-endemic countries, coupled with one-time screening in the general 
population[20–22]. Indeed, in Portugal, screening every three years presented an ICER of 34,000D 
/QALY in high-risk regions, while amongst MSM and IDUs, even annual screening yielded D 
21,000/QALY and D 30,000/QALY [20]. Similarly, in France, annual HIV screening resulted in 
51,200D /QALY for IDUs and 46,500D /QALY for French Guyana residents [21]. Differently, while 
one-time testing for MSM was 32,400D /QALY compared to current practice, annual screening 
would be more expensive (97,200D /QALY) [21]. Lucas et al. investigated the optimal frequency of 
repeated screening in different groups highlighting the following results: screening every 9 months 
for medium-risk (0.1%) and 3 months for high-risk incidence [28]. Annual testing for medium- and 
high-risk groups would cost less than $100,000 per QALY, while testing every 5 years would cost 
less than 50,000 $/QALY [28]. Screening high-risk individuals every 3 months compared with annual 
testing presented a gain of0.03 QALYs with an additional cost of $1357 per person [28].In the high-
risk groups (HIV-undiagnosed prevalence: 3.0%), the benefits of the screening were remarkable, 
increasing the mean count of CD4 at diagnosis, decreasing the rate of opportunistic infections and 
improving survival [44]. All the above mentioned benefits further increased using repeated testing 
[44]. For example, one-time screening presented a mean CD4 cell count at a detection of 210 rather 
than 154 per cubic millimetre with no screening; moreover, testing every five years further raised 
CD4 cell counts at detection among incident cases (347–397 per cubic millimetre)and significantly 
reduced to 16% the proportion of cases detected with an opportunistic infection [44]. Considering the 
threshold of $100,000/QALY, all the screening programmes (one time, every five years, every three 
years, annually) was cost-effective in high-risk communities [44]. Similarly, considering moderate 
prevalence and incidence, all screening strategies (one time, every five or three years) would cost less 
than 100,000 $/QALY [43]. Considering exclusively MSM, one recent study investigated the impact 
of different screening strategies as symptom-based viral load (VL), annual routine antibody testing 
or the addition to routine antibody testing of viral load. Annual routine antibody screening effectively 
reduced new infections (reduction of 2,8%) at a cost of $12,582/QALY. The symptom-based VL 
yielded greater health benefits (reduction of 5,7% in new infections) at a cost of $22,786/QALY. The 
integration of these two strategies was associated with the greatest health benefits (averting nearly 
40,000 new infections –7.2%) infections averted, at a cost of $29,923/QALY [24]. Similarly, another 
US study assessed the potential role of an alternative type of test such as standard testing or NAAT, 
assessing the optimal frequency utilization of this analysis [40]. In this case, choosing a standard 
targeted screening for high-risk groups (MSM, IDU) showed more favourable ratios (annual testing 
<$10,000/QALY, 6-months <$20,000/QALY). Moreover, annual targeted NAAT (MSM and IDU or 
MSM only) presented an ICER slightly under 100,000$/QALY; by contrast, semi-annual NAAT 
testing was far less economically efficient [40]. 
3.4. Particular settings  
We retrieved 12 studies considering exclusively the cost-effectiveness of HIV-screening in specific 
settings (see Tables 3 and 4) [23,25–27,45–52]. The majority of the authors chose a societal 
perspective [23,25,26,46,47,48,50,52]. All studies adopted a long-term perspective [23,25–27,45–
52]. For the economic analysis, the reference year ranged from 1999 [52] to 2009 [23,25,26,27,45–
48,50], adopting a discounting rate ranging from3% [23,25–27,45–50,52] to 4% [51]. 
3.5. Healthcare settings  
In this context, the most commonly studied setting was the emergency department (ED) 
[27,45,47,48]. Two studies assessed the cost-effectiveness of HIV screening for ED patients 
compared to the standard diagnostic approach [45,47]. Both studies outlined the health benefits of 
similar interventions, as additional cases individuated [45] or secondary transmissions prevented 
(preventing 2.1 HIV transmission events over 16 months) [47]. Economically, Haukoos et al. 
modelled the cost-effectiveness considering the intermediate outcome of additional new infections 
identified. In such terms, routine screening would cost $10,693 per additional new infection identified 
[45]. Conversely, Dowdy et al. used the direct outcome of quality-adjusted life-years, per patient 
screened, targeted screening saved $112 and resulted in 2.71 quality-adjusted life-days gained [47]. 
Both studies identified as more influencing parameters the testing costs and the undiagnosed HIV 
prevalence[45,47]. ED screening remained below $35,000/QALY even at a 0.1% prevalence 
($35,000/QALY) [47]. In more detail, a recent study assessed the HIV screening carried out by ED 
staff (provider-based) or by HIV counsellors (counsellor-based). The key difference was the coverage 
rate of the testing, respectively 27% in the provider programme and 57% in the counsellor programme 
[48]. Considering costs, the provider and counsellor strategies presented an average cost of $8.10 and 
$31.00 per result received, respectively [48]. In the sensitivity analysis, the findings appeared 
sensitive to offer and acceptance rates but were robust considering variations in undiagnosed HIV 
prevalence and programmatic costs [48]. 
 
 
 
 
An additional study focused on routine screening in EDs, com-pared to diagnostic testing upon 
symptomatic manifestations. Assessing the screening impact on secondary transmissions, universal 
testing in EDs was cost-saving, adding an additional 2.5(2.3–2.6) QALYs [27]. Compared to standard 
diagnosis in inpatient settings, the cost per QALY for screening in the ED setting was$34,597 [27]. 
More broadly, Walensky et al. studied the implementation of routine HIV screening for all inpatients 
in US hospitals, assuming a moderate acceptance rate of 37%. This screening presented significant 
health benefits such as additional quality-adjusted life months, a higher CD4 count at diagnosis and 
reduction of opportunistic infections at diagnosis [50]. The screening was below $100,000/QALY 
both in cases of high HIV prevalence (1%) ($35,400/QALY) and considering the lower prevalence 
of 0.1% ($64,500/QALY). As expected, programmes with a higher acceptance rate were more 
economically attractive [50]. Another interesting healthcare setting is primary care (general, family 
practice and internal medicine). In this environment, Phillips et al. considered two approaches such 
as universal HIV testing or targeted high-risk testing. High-risk subjects were individuated through a 
behavioural assessment. It was assumed that approximately 31% of users presented at least one risk 
factor. Therefore, routine screening would cost $22,000/QALY gained. In the sensitivity analysis, the 
targeted strategy became more favourable when individuals at risk were below 23% or the cost of 
risk assessment decreased. Moreover, considering a behavioural impact higher than 10%, both routine 
and targeted testing appeared to be cost saving [52]. The behavioural impact of HIV screening 
consisted of a reduction of at-risk behaviour among tested people; in particular, it translated to a 
reduction of sexual transmissions [52]. Given the importance of HIV screening in primary care, in 
this setting, Sanders et al. investigated the role of different approaches, such as traditional HIV testing 
and counselling, nurse-initiated HIV screening or nurse-initiated screening through a rapid test. Both 
nurse strategies presented better test acceptance and result receipt compared to the standard approach. 
Precisely, the better option was nurse-initiated rapid testing [23]. Moreover, the implementation of 
HIV testing was assessed for outpatients presenting fever or other viral symptomatology. The authors 
investigated the impact of different tests, such as p24 antigen EIA, HIV-RNA or 3rd-generation EIA. 
The most cost-effective programme offered p24 antigen EIA with a cost-effectiveness ratio of 
$30,800/QALY, preventing over 400 new infections [26]. 
3.6. STD clinics  
The implementation of HIV screening in STD clinics occurred in two studies [27,51]. The 
implementation of HIV screening in STD clinics, compared to diagnostic testing upon symptomatic 
manifestations, yielded, excluding the effect of HIV transmission, 34.597$/QALY at a CD4 cell count 
of 350 cells/L, similarly to ED screening, where treatment with HAART for the index patient was 
initiated at a CD4 count of 500 cells/L, whereas an ICER of approximately $60,000 per QALY was 
gained at a CD4 count of 500 cells/L in STD clinic settings. [27]. Similarly, a European study in this 
same setting reported D 2987/LYG with a similar screening. Likewise, assuming a lower behavioural 
impact (20%), the intervention presented an ICER of13,438D /LYG [51]. The authors also considered 
health benefits gained, such as CD4 count, opportunistic infections, the mean time from infection to 
the start of HAART and the avoidance of HIV infection in partners [27,51]. The difference of the 
results presented in the studies could be imputed to the different costs included in the analysis. For 
example, one study excluded the research-related and start-up costs from the model [27].  
3.7. Substance abuse treatment programmes 
One commonly identified high-risk group are IDUs. Two studies assessed the role of HIV screening 
in substance abuse treatment programmes [25,46]. The more recent study considered three different 
strategies, specifically, off-site referral for testing and on-site rapid test with or without counselling. 
The best option appeared to be on-site testing with an ICER of $60,300/QALY, dominating the off-
site referral option. In the sensitivity analysis, offering a rapid test in this setting was 
<$100,000/QALY, even in case of low HIV prevalence (0.1%). In contrast, the addition of 
counselling did not bring any additional health benefit [25]. The second study considered HIV 
screening during opioid replacement therapy (ORT). Offering HIV screening in this setting averted 
up to 28 new infections, depending on the testing frequency. However, adding HIV-RNA testing, in 
order to identify acute infections, prevented more cases than simply increasing the screening 
frequency. Screening for HIV antibodies every 6 months cost $30,700/QALY gained, whereas 
screening for HIV antibodies and viral RNA every 6months had an ICER of $65,900/QALY gained 
compared to screening annually [46]. The present studies underlined the individual health benefits of 
HIV screening in terms of disease progression, mortality and transmission from sexual partnerships 
and injection equipment sharing through risk-structured mass action [46]. 
3.8. Sex workers 
Even if most studies outlined the necessity to increase the screening frequency in specific settings, 
this is not always the case. Indeed, one paper regarding female sex workers highlighted an excess in 
testing under the current policy in Australia, where sex workers undertook HIV testing every three 
months. At the actual incidence rate (HIV: 0.1/100), the current screening strategy would cost over 
$A4,000.000 for every HIV infection averted and $A10,000.000 for each QALY saved. Screening 
remained under $A50,000 per QALY gained only with a testing frequency below 40 weeks [49]. 
 
 
4. Discussion 
Given the well-established benefits, both individual and collective, of early HIV diagnosis, the 
implementation of HIV screening appears extremely important [3–6]. The scientific evidence 
regarding HIV screening is variegated, considering the screening approach, the type of test, the testing 
frequency and the target population [4,20–22,24,39,52]. To identify the most favourable strategy, 
policymakers have required accurate cost-effectiveness investigations. Then, the aim of our review 
was to summarize the available evidence regarding the cost-effectiveness of HIV screening, 
concentrating on high-income countries as more comparable. First, the cost-effectiveness of one-time 
screening for the general population was widely assessed in all the considered countries [4,20–
22,28,39–43]. In their sensitivity analysis, these studies outlined the cost-effectiveness of similar 
programmes, even at an extremely low HIV prevalence [39–43]. In some countries with a higher 
HIV-burden, such as Russia or Portugal, even repeated screening in the general population was cost-
effective [20,42]. Therefore, offering one-time screening to the general population appeared 
desirable, even in cases of an HIV prevalence lower than the CDC recommendations for screening 
implementation [10]. Moreover, the expansion of HIV screening to older cohorts seemed 
economically attractive in many circumstances, particularly whenever the prevalence exceeded 0.1% 
[53]. In addition, repeated screening of the general population could be useful in cases of a moderate 
prevalence and incidence rate [42]. Furthermore, the repeated screening of high-risk groups appeared 
particularly interesting. Indeed, annual screening of IDUs or of people from endemic countries fell 
well within the cost-effectiveness limits [20–22,39,42]. The decision regarding the optimal testing 
frequency requires further studies and depends primarily on the HIV prevalence and incidence [20–
22,39,42]. Indeed, with an increasing HIV burden, repeated screening has become increasingly more 
attractive [20–22,39,42]. Another important theme is the correct selection of high-risk groups and the 
individuation of effective strategies to reach them. Thus, information campaigns and appropriate 
counselling appear important in order to increase test acceptance. All the retrieved studies agreed 
about the importance of increase testing uptake [20–22,39,42]. In this sense, an important function 
could be carried out by stigma reduction. It must be taken into account that programmes proposed as 
routine testing reach higher acceptance than those presented as targeted towards at-risk sub-
populations [54,55]. Another important parameter in determining cost-effectiveness is the impact 
upon behavioural changes [20–22,41,44]. Consequently, the efforts to minimize at-risk behaviours 
should be accentuated. Precisely, the programmes aiming to reduce risky behaviours appear to be a 
key component of HIV screening success. Moreover, the impact of HIV screening upon risk 
behaviours may be underestimated; indeed, some studies exclusively assessed the effect on sexual 
behaviours, ignoring the potential impact on other behaviours, such as needle sharing [20,42]. 
However, even in the worst-case scenario, the screening stayed cost-effective [21,22,25,42,47,50]. In 
particular, the attractiveness of screening was established using both standard and rapid testing 
[21,22,28,39,41]. However, some studies highlighted the advantages, even economic, of rapid testing 
[9,28]. Indeed, a rapid test, with its same-day results, maximizes the receipt rate. This is extremely 
important considering the influence of loss to follow-up on cost-effectiveness [20,21,42]. In addition, 
the impact of testing costs was investigated, highlighting the screening cost-effectiveness within a 
wide range of plausible costs. Another component of testing costs considered was counselling. The 
findings were heterogeneous. In particular, the addition of counselling to IDU screening did not 
present any additional benefit but was associated with a lower acceptance rate [25]. In older cohorts, 
the implementation of abbreviated counselling was linked with increased health benefits and a more-
attractive ICER [53]. In EDs, counselling by HIV specialists is associated with higher acceptance 
[48]. In primary care, nurse counselling appears to be more favourable than the standard medical 
approach [52]. In summary, the optimal counselling strategy should be further investigated, also 
depending on different settings considered. In particular, it may be interesting to assess the exact 
impact of counselling on behavioural changes and secondary transmissions. One study outlined the 
importance of HIV screening as a component of a larger HIV prevention project. Indeed, integrative 
programmes work better than individual ones, presenting synergistic effects [46]. Therefore, it 
appears important to choose the most effective strategies to implement together, considering the 
potential complementary effects. The cost-effectiveness of HIV screening was assessed in a limited 
number of high-income countries. However, as several countries appear comparable in terms of 
resources and HIV burden, the retrieved results are widely applicable. Moreover, in the sensitivity 
analysis, a wide range of scenarios was tested, proving the robustness of the retrieved findings [4,20–
22,28,39–43]. Another issue emerging from our review was related to HIV acute infections. The 
impact of acute infection on overall HIV transmission is not negligible. Therefore, some studies have 
focused on specific programmes to identify these infections [24,26,40]. The most cost-effective test, 
in this case, appeared to be a 4th generation ELISA test or more specific and expensive tests targeted 
towards high-incidence subpopulations [40]. Another cost-effective approach was testing outpatients 
reporting fever or viral symptoms [26]. In summary, the investigation of acute infections appeared 
interesting, especially considering high-incidence groups. The most cost-effective strategy must be 
chosen depending on the HIV burden, specific setting and population. The main limitations consisted 
of the heterogeneity of the results and strategies tested. Indeed, the studies retrieved employed non-
uniform values as cost-effectiveness thresholds. Inasmuch, some authors choose the traditional value 
of $100,000/QALY [21,44,53], while others set a lower limit of $50,000/QALY [4,26] or 
$75,000/QALY [23]. Furthermore, other studies have considered the suggested WHO thresholds 
[20]. Actually, the exact cost-effectiveness threshold is still debated [30]. Nonetheless, all the studies 
have outlined the economic and health attractiveness of these programmes. Moreover, HIV screening 
favourably compares with other screenings taking place in the considered countries [21,41,50]. 
Another source of heterogeneity is represented by the different types of costs included in the studies. 
In particular, it appeared difficult to correctly estimate all the indirect costs, such as losses of 
productivity. These issues are partially resolved by testing a wide range of costs in the sensitivity 
analysis. Additional limitations are attributable to the lack of accurate data; most were estimates of 
HIV prevalence and incidence, the costs of HIV testing and therapies. However, the cost-
effectiveness of HIV screening appeared robust across various scenarios, even considering costs 
higher than the current value and an HIV prevalence lower than those experienced in most countries. 
Furthermore, the studies employed conservative estimates. Consequently, the real cost-effectiveness 
of HIV screening could be even underscored. Finally, most papers used mathematical models, 
therefore simplifying the real progression of HIV disease and estimating the long-term consequences 
based on multiple and heterogeneous sources. However, in this case, the wide assumptions used in 
the sensitivity analysis could effectively control this issue. One additional limitation of our review 
and, in general, of the literature available regarding the topic of interest, is the lack of observational 
studies of cost-effectiveness. Some direct experience of universal screening worldwide existed, but 
the economic analyses in this regard are scarce or have a very short time horizon. Possibly, in the 
next years, information regarding these experiences will grow, providing more direct data for 
economic and cost-utility analyses. Since the choice of the correct threshold may be difficult, we also 
compare HIV screening with other interventions in the field of HIV prevention. Interestingly, HIV 
screening favourably compares with this strategy and may be a part of a larger programme. For 
example, antenatal HIV screening has been considered cost-effective in several studies [56]. In 
addition, increasing antiretroviral use to 75% of eligible patients would be cost-effective 
($20,300/QALY) [22]. Integrating this latter strategy with HIV screening would be very cost-
effective ($21,580/QALY) [22]. 
 
5. Conclusion 
In conclusion, the evidence regarding the health benefits and cost-effectiveness of HIV screening is 
growing, even in low-prevalence countries. The major determinant of cost-effectiveness remains the 
baseline HIV prevalence. In particular, in high-risk groups, repeated testing is especially attractive, 
while in the general population, one-time screening is worthwhile. From our review, both standard 
and rapid testing are cost-effective. However, increasing evidence outlines the benefits of rapid 
testing. Further studies are required to define the optimal screening frequency in both general and 
high-risk populations. However, despite the high heterogeneity of the retrieved studies, scientific 
evidence suggests the cost-effectiveness of HIV screening in multiple populations and settings. 
Another important, emerging topic is the impact of counselling. Further studies are required to exactly 
define the best screening strategy considering the potential role of less-expensive, abbreviated 
counselling. Finally, our analysis highlighted the cost-effectiveness of HIV screening implementation 
even with higher frequencies and in populations with a lower prevalence than those recommended by 
the CDC [10]. The extension of HIV screening, even to older cohorts, is particularly interesting. 
However, the feasibility of similar choices should be weighed considering the available resources. 
Furthermore, the attractiveness of the screening programme was extensively outlined in specific 
settings such as EDs, primary care, STD clinics and substance abuse treatment programmes. In 
conclusion, our review may provide some useful directions to policy-makers, as follows: 
• One-time screening offered to adult populations appears to be avaluable choice; 
• Repeated testing in high-risk groups such as IDUs and MSM is an important tool in the field of HIV 
prevention; 
• The evidence regarding the benefits of the use of rapid tests, even in terms of cost-effectiveness, is 
growing; 
• Specific settings, such as STD clinics or EDs, may play an importan trole in offering HIV testing; 
• HIV screening may be beneficial even in selected cohorts of older patients, according to the baseline 
prevalence in these groups. 
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